Cargando…
Lessons from the COVID-19 pandemic and recent developments on the communication of clinical trials, publishing practices, and research integrity: in conversation with Dr. David Moher
BACKGROUND: The torrent of research during the coronavirus (COVID-19) pandemic has exposed the persistent challenges with reporting trials, open science practices, and scholarship in academia. These real-world examples provide unique learning opportunities for research methodologists and clinical ep...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383655/ https://www.ncbi.nlm.nih.gov/pubmed/35978325 http://dx.doi.org/10.1186/s13063-022-06624-y |
_version_ | 1784769403365097472 |
---|---|
author | Lawson, Daeria O. Wang, Michael K. Kim, Kevin Eikelboom, Rachel Rodrigues, Myanca Trapsa, Daniela Thabane, Lehana Moher, David |
author_facet | Lawson, Daeria O. Wang, Michael K. Kim, Kevin Eikelboom, Rachel Rodrigues, Myanca Trapsa, Daniela Thabane, Lehana Moher, David |
author_sort | Lawson, Daeria O. |
collection | PubMed |
description | BACKGROUND: The torrent of research during the coronavirus (COVID-19) pandemic has exposed the persistent challenges with reporting trials, open science practices, and scholarship in academia. These real-world examples provide unique learning opportunities for research methodologists and clinical epidemiologists-in-training. Dr. David Moher, a recognized expert on the science of research reporting and one of the founders of the Consolidated Standards of Reporting Trials (CONSORT) statement, was a guest speaker for the 2021 Hooker Distinguished Visiting Professor Lecture series at McMaster University and shared his insights about these issues. MAIN TEXT: This paper covers a discussion on the influence of reporting guidelines on trials and issues with the use of CONSORT as a measure of quality. Dr. Moher also addresses how the overwhelming body of COVID-19 research reflects the “publish or perish” paradigm in academia and why improvement in the reporting of trials requires policy initiatives from research institutions and funding agencies. We also discuss the rise of publication bias and other questionable reporting practices. To combat this, Dr. Moher believes open science and training initiatives led by institutions can foster research integrity, including the trustworthiness of researchers, institutions, and journals, as well as counter threats posed by predatory journals. He highlights how metrics like journal impact factor and quantity of publications also harm research integrity. Dr. Moher also discussed the importance of meta-science, the study of how research is carried out, which can help to evaluate audit and feedback systems and their effect on open science practices. CONCLUSION: Dr. Moher advocates for policy to further improve the reporting of trials and health research. The COVID-19 pandemic has exposed how a lack of open science practices and flawed systems incentivizing researchers to publish can harm research integrity. There is a need for a culture shift in assessing careers and “productivity” in academia, and this requires collaborative top-down and bottom-up approaches. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06624-y. |
format | Online Article Text |
id | pubmed-9383655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93836552022-08-17 Lessons from the COVID-19 pandemic and recent developments on the communication of clinical trials, publishing practices, and research integrity: in conversation with Dr. David Moher Lawson, Daeria O. Wang, Michael K. Kim, Kevin Eikelboom, Rachel Rodrigues, Myanca Trapsa, Daniela Thabane, Lehana Moher, David Trials Commentary BACKGROUND: The torrent of research during the coronavirus (COVID-19) pandemic has exposed the persistent challenges with reporting trials, open science practices, and scholarship in academia. These real-world examples provide unique learning opportunities for research methodologists and clinical epidemiologists-in-training. Dr. David Moher, a recognized expert on the science of research reporting and one of the founders of the Consolidated Standards of Reporting Trials (CONSORT) statement, was a guest speaker for the 2021 Hooker Distinguished Visiting Professor Lecture series at McMaster University and shared his insights about these issues. MAIN TEXT: This paper covers a discussion on the influence of reporting guidelines on trials and issues with the use of CONSORT as a measure of quality. Dr. Moher also addresses how the overwhelming body of COVID-19 research reflects the “publish or perish” paradigm in academia and why improvement in the reporting of trials requires policy initiatives from research institutions and funding agencies. We also discuss the rise of publication bias and other questionable reporting practices. To combat this, Dr. Moher believes open science and training initiatives led by institutions can foster research integrity, including the trustworthiness of researchers, institutions, and journals, as well as counter threats posed by predatory journals. He highlights how metrics like journal impact factor and quantity of publications also harm research integrity. Dr. Moher also discussed the importance of meta-science, the study of how research is carried out, which can help to evaluate audit and feedback systems and their effect on open science practices. CONCLUSION: Dr. Moher advocates for policy to further improve the reporting of trials and health research. The COVID-19 pandemic has exposed how a lack of open science practices and flawed systems incentivizing researchers to publish can harm research integrity. There is a need for a culture shift in assessing careers and “productivity” in academia, and this requires collaborative top-down and bottom-up approaches. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06624-y. BioMed Central 2022-08-17 /pmc/articles/PMC9383655/ /pubmed/35978325 http://dx.doi.org/10.1186/s13063-022-06624-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary Lawson, Daeria O. Wang, Michael K. Kim, Kevin Eikelboom, Rachel Rodrigues, Myanca Trapsa, Daniela Thabane, Lehana Moher, David Lessons from the COVID-19 pandemic and recent developments on the communication of clinical trials, publishing practices, and research integrity: in conversation with Dr. David Moher |
title | Lessons from the COVID-19 pandemic and recent developments on the communication of clinical trials, publishing practices, and research integrity: in conversation with Dr. David Moher |
title_full | Lessons from the COVID-19 pandemic and recent developments on the communication of clinical trials, publishing practices, and research integrity: in conversation with Dr. David Moher |
title_fullStr | Lessons from the COVID-19 pandemic and recent developments on the communication of clinical trials, publishing practices, and research integrity: in conversation with Dr. David Moher |
title_full_unstemmed | Lessons from the COVID-19 pandemic and recent developments on the communication of clinical trials, publishing practices, and research integrity: in conversation with Dr. David Moher |
title_short | Lessons from the COVID-19 pandemic and recent developments on the communication of clinical trials, publishing practices, and research integrity: in conversation with Dr. David Moher |
title_sort | lessons from the covid-19 pandemic and recent developments on the communication of clinical trials, publishing practices, and research integrity: in conversation with dr. david moher |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383655/ https://www.ncbi.nlm.nih.gov/pubmed/35978325 http://dx.doi.org/10.1186/s13063-022-06624-y |
work_keys_str_mv | AT lawsondaeriao lessonsfromthecovid19pandemicandrecentdevelopmentsonthecommunicationofclinicaltrialspublishingpracticesandresearchintegrityinconversationwithdrdavidmoher AT wangmichaelk lessonsfromthecovid19pandemicandrecentdevelopmentsonthecommunicationofclinicaltrialspublishingpracticesandresearchintegrityinconversationwithdrdavidmoher AT kimkevin lessonsfromthecovid19pandemicandrecentdevelopmentsonthecommunicationofclinicaltrialspublishingpracticesandresearchintegrityinconversationwithdrdavidmoher AT eikelboomrachel lessonsfromthecovid19pandemicandrecentdevelopmentsonthecommunicationofclinicaltrialspublishingpracticesandresearchintegrityinconversationwithdrdavidmoher AT rodriguesmyanca lessonsfromthecovid19pandemicandrecentdevelopmentsonthecommunicationofclinicaltrialspublishingpracticesandresearchintegrityinconversationwithdrdavidmoher AT trapsadaniela lessonsfromthecovid19pandemicandrecentdevelopmentsonthecommunicationofclinicaltrialspublishingpracticesandresearchintegrityinconversationwithdrdavidmoher AT thabanelehana lessonsfromthecovid19pandemicandrecentdevelopmentsonthecommunicationofclinicaltrialspublishingpracticesandresearchintegrityinconversationwithdrdavidmoher AT moherdavid lessonsfromthecovid19pandemicandrecentdevelopmentsonthecommunicationofclinicaltrialspublishingpracticesandresearchintegrityinconversationwithdrdavidmoher |